CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
新型细胞疗法和双特异性T细胞衔接抗体的开发正在多发性骨髓瘤（MM）领域以惊人的速度推进。尽管这些药物具有突破性，但它们各自存在独特的物流和毒性问题，且目前尚不能代表一种治愈性方法。在此背景下，仍然迫切需要开发新型的即用型免疫治疗方法，以充实治疗武器库。本文探讨了正在与标准免疫调节药物以及下一代cereblon E3连接酶调节剂联合研究的新型药物。这些新型药物包括从其他疾病用途中重新定位的药物以及新型单克隆抗体。此外，还综述了正在开发中的药物，如免疫细胞因子、免疫毒素和NK 细胞激活剂/衔接剂。这些新型治疗策略有望逆转免疫抑制性肿瘤微环境，从而增强抗MM活性。
The development of novel cellular therapies and bispecific T-cell-engaging antibodies is occurring at breakneck speed in multiple myeloma (MM). While groundbreaking, these agents have their unique logistical and toxicity issues and currently do not represent a curative approach. In this context, there continues to be an urgent need to develop novel, off-the-shelf immunotherapy approaches to add to the armamentarium.
This article explores novel agents being investigated in combination with standard immunomodulatory drugs as well as next-generation cereblon E3 ligase modulators. These novel agents include drugs being repurposed from their use in other diseases as well as novel monoclonal antibodies.
In addition, agents under development such as immunocytokines, immunotoxins, and natural killer-cell activators/engagers are reviewed. These novel therapeutic strategies hold the promise of countermanding the immunosuppressive tumor microenvironment, leading to enhanced anti-MM activity.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
